High Implantation of Self-Expanding Valves in the Aortic Position or Cusp Overlapping: Should It Be the New “Gold Standard”?

Transcatheter aortic valve replacement (TAVR) has been proving its benefit in different scenarios for two decades now. However, in the field of self-expanding valves, one challenge has always been its high rate of pacemaker implantation compared with balloon-expandable devices and valvular replacement surgery.

Implante alto de las válvulas autoexpandibles en posición aórtica

For this reason, the high implantation or Cusp Overlapping strategy was developed. This alternative has demonstrated in different analyses a lower need for definitive pacemaker after implantation, but to date there are only small studies and no randomized or large studies.

Researchers conducted a meta-analysis of 11 (non-randomized) studies, which included 3207 patients. Of them, 1464 (45.6%) had a Cusp Overlapping (COVL), while 1743 had a tricuspid coplanar implantation (COP).

The primary endpoint (PEP) was permanent pacemaker implantation.

The PEP was in favor of the COVL group (odds ratio: 0.48; 95% confidence interval [CI]: 0.33-0.70; p = 0.001). Among these patients, there was also a higher implant compared with the COP group (mean difference: -0.83; 95% CI: -1.2 to -0.45; p < 0.001).

Read also: Drug-Eluting Balloon in STEACS: Leaving No Trace is Beneficial?

There was no statistically significant difference regarding the presence of new left bundle branch block, moderate or severe paravalvular leak, need for a second valve, stroke, mortality, crossover to surgery, coronary obstruction, and gradient after implantation.

Conclusion

In TAVR with self-expandable valves, implantation with COVL was associated with lower risk of definitive pacing compared with the COP strategy, with no increased risk of adverse events.

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the Editorial Board of SOLACI.org.

Original Title: Cusp‐overlap versus coplanar view in transcatheter aortic valve implantation with self‐expandable valves: A meta‐analysis of comparative studies.

Reference: Michel Pompeu Sá, et al. Catheter Cardiovasc Interv. 2023;101:639–650.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Measuring Post-TAVI Gradients and Their Implications: Are Invasive and Echocardiographic Assessments Comparable?

Transcatheter aortic valve implantation (TAVI) is considered the treatment of choice for a significant proportion of patients with symptomatic aortic stenosis. Outcomes have improved...

Percutaneous Tricuspid Valve Replacement with Lux-Valve

Tricuspid regurgitation (TR) is a condition associated with poor quality of life, frequent hospitalizations due to heart failure, and increased mortality, even under optimal...

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Pretreatment with DAPT in Acute Coronary Syndrome: An Ongoing Debate?

In acute coronary syndrome (ACS) dual antiplatelet therapy (DAPT) has become a fundamental pillar after percutaneous coronary intervention (PCI), preventing stent thrombosis and acute...

Measuring Post-TAVI Gradients and Their Implications: Are Invasive and Echocardiographic Assessments Comparable?

Transcatheter aortic valve implantation (TAVI) is considered the treatment of choice for a significant proportion of patients with symptomatic aortic stenosis. Outcomes have improved...

Another Blow for Intra-Aortic Balloon Pumo Counterpulsation? Randomized Study on Its Use in Chronic Heart Failure Progressing to Cardiogenic Shock

Cardiogenic shock (CS) remains a condition with extremely high mortality (around 50%). While most therapies for this pathology have been studied in CS secondary...